The Resource Global health perspectives in prediabetes and diabetes prevention, Michael Bergman, editor

Global health perspectives in prediabetes and diabetes prevention, Michael Bergman, editor

Label
Global health perspectives in prediabetes and diabetes prevention
Title
Global health perspectives in prediabetes and diabetes prevention
Statement of responsibility
Michael Bergman, editor
Contributor
Subject
Genre
Language
  • eng
  • eng
Summary
This comprehensive text is unique in its compilation of experiences in addressing the global diabetes epidemic and description of diverse worldwide prevention initiatives. Background chapters describe the diagnosis and definition of diabetes, the epidemiology, pathophysiology of prediabetes as well as clinical trial evidence for diabetes prevention and treatment. Furthermore, the critical role of government in formulating a global health agenda, policy perspectives for European initiatives, the importance of nutritional policies for diabetes prevention as well as the development of the necessa
Cataloging source
MiAaPQ
Dewey number
  • 362.1964/62
  • 616.462
Illustrations
illustrations
Index
index present
Language note
English
LC call number
RA645.D5
LC item number
.G56 2014
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
http://library.link/vocab/relatedWorkOrContributorName
Bergman, Michael
http://library.link/vocab/subjectName
  • Diabetes
  • Diabetes
Label
Global health perspectives in prediabetes and diabetes prevention, Michael Bergman, editor
Instantiates
Publication
Copyright
Note
Description based upon print version of record
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Content category
text
Content type code
  • txt
Contents
  • Contents; Preface; REFERENCES; Chapter 1: Diagnosis and Definition; 1. THE PAST HISTORY OF "GLUCOSE INTOLERANCE"; 2. THE MODERN ERA OF "PREDIABETES"; 2.1. Step 1; 2.2. Step 2; 2.3. Step 3; 2.4. Is HbA1c [5.7-6.4%] the Gold Standardfor Prediabetes?; 2.4.1. Pro; 2.4.2. Contra; 2.5. Is Prediabetes Really the First "Pathological" Threshold?; 3. CURRENT STATUS OF PREDIABETES; REFERENCES; Chapter 2: Epidemiology of Prediabetes; 1. BACKGROUND; 2. DEFINITIONS OF PREDIABETES; 2.1. Intermediate Hyperglycemia (IGT and IFG); 2.1.1. Impaired glucose tolerance; 2.1.2. Impaired fasting glucose
  • 2.2. Glycated Hemoglobin (HbA1c)2.3. Risk Assessment Tools; 3. CONCLUSIONS; REFERENCES; Chapter 3: Pathophysiology of Prediabetes: Role of Lipotoxicity?; 1. INTRODUCTION; 2. β-CELL DYSFUNCTION AND INSULIN RESISTANCE; 3. ABDOMINAL OBESITY AND ECTOPIC FAT; 4. LIPOTOXICITY AND GLUCOTOXICITY; 5. MARKERS OF PROGRESSION FROM IGTTO TYPE 2 DIABETES; 6. CONCLUSIONS; REFEREN CES; Chapter 4: Primary Prevention Trials in Type 2 Diabetes; 1. INTRODUCTION; 1.1. Burden of Type 2 Diabetes; 2. PRIMARY PREVENTION OF DIABETES; 2.1. Risk Factors; 2.2. Types of Intervention; 3. INTERVENTION STRATEGIES
  • 3.1. Lifestyle Modification (LSM)3.2. The China Da Qing Study10; 3.3. The Finnish Diabetes Prevention Study (DPS)11; 3.4. The Diabetes Prevention Program (DPP)12/The DPP Outcome Study (DPPOS)20; 4. STUDIES IN ASIAN POPULATIONS; 4.1. The Indian Diabetes Prevention Programs (IDPP)13; 4.2. Japanese Diabetes Prevention Studies; 4.3. Malmo Feasibility Study22; 5. RECENT DEVELOPMENTS; 5.1. Efficacy of Mobile Phone Messaging in Prevention of Diabetes24; 6. STUDIES USING PHARMACOLOGICAL AGENTS; 6.1. Metformin; 6.2. Alpha Glucosidase Inhibitors; 6.3. Thiazolidinediones (TZD)
  • 6.4. The CAnadian Normoglycemia Outcomes Evaluation Trial316.5. Studies Using Other Drugs; 6.6. Antihypertensive Agents; 6.7. Safety of Pharmacological Agents; 7. MECHANISM OF ACTION OF INTERVENTION; 7.1. Cost-Effectiveness of Prevention Programs; 8. NATIONAL PROGRAMS; 9. CONCLUSIONS; REFERENCES; Chapter 5: Treatment of Prediabetes; 1. INTRODUCTION; 2. PATHOGENESIS OF T2DM; 2.1. Insulin Resistance; 2.2. Impaired β-Cell Function; 3. INSULIN RESISTANCE AND β-CELLFUNCTION IN IFG AND IGT; 4. INTERVENTION TO PREVENT THE PROGRESSION OF IGT TO T2DM; 4.1. Reversal of Insulin Resistance: Weight Loss
  • 4.2. Reversal of Insulin Resistance: Pharmacologic Intervention4.2.1. Metformin; 4.2.2. Thiazolidinediones (TZDs); 4.3. Preservation of β-Cell Function; 4.3.1. Glucagon-like Peptide-1 (GLP-1) Analogs; 4.3.2. DPP-IV inhibitors; 4.4. α-Glucosidase Inhibitors; 5. IDENTIFICATION OF HIGH-RISK IGT INDIVIDUALS FOR PHARMACOLOGICAL THERAPY; 6. APPROACH TO THE PATIENT WITH PREDIABETES; 7. SUMMARY; 8. CONCLUSION; REFERENCES; Chapter 6: Diabetes Prevention and Nutrition Policies from a Global Perspective; 1. INTRODUCTION; 2. PRIMARY PREVENTION; 2.1. Addressing Overweight and Obesity
  • 2.2. Increasing Physical Activity and Reducing Sedentary Behavior
Dimensions
unknown
Extent
1 online resource (498 p.)
Form of item
online
Isbn
9789814603324
Media category
computer
Media type code
  • c
Specific material designation
remote
System control number
  • (CKB)3710000000214664
  • (EBL)1766818
  • (SSID)ssj0001287768
  • (PQKBManifestationID)12486918
  • (PQKBTitleCode)TC0001287768
  • (PQKBWorkID)11291271
  • (PQKB)10125267
  • (MiAaPQ)EBC1766818
  • (WSP)00009170
  • (EXLCZ)993710000000214664
Label
Global health perspectives in prediabetes and diabetes prevention, Michael Bergman, editor
Publication
Copyright
Note
Description based upon print version of record
Bibliography note
Includes bibliographical references and index
Carrier category
online resource
Carrier category code
  • cr
Content category
text
Content type code
  • txt
Contents
  • Contents; Preface; REFERENCES; Chapter 1: Diagnosis and Definition; 1. THE PAST HISTORY OF "GLUCOSE INTOLERANCE"; 2. THE MODERN ERA OF "PREDIABETES"; 2.1. Step 1; 2.2. Step 2; 2.3. Step 3; 2.4. Is HbA1c [5.7-6.4%] the Gold Standardfor Prediabetes?; 2.4.1. Pro; 2.4.2. Contra; 2.5. Is Prediabetes Really the First "Pathological" Threshold?; 3. CURRENT STATUS OF PREDIABETES; REFERENCES; Chapter 2: Epidemiology of Prediabetes; 1. BACKGROUND; 2. DEFINITIONS OF PREDIABETES; 2.1. Intermediate Hyperglycemia (IGT and IFG); 2.1.1. Impaired glucose tolerance; 2.1.2. Impaired fasting glucose
  • 2.2. Glycated Hemoglobin (HbA1c)2.3. Risk Assessment Tools; 3. CONCLUSIONS; REFERENCES; Chapter 3: Pathophysiology of Prediabetes: Role of Lipotoxicity?; 1. INTRODUCTION; 2. β-CELL DYSFUNCTION AND INSULIN RESISTANCE; 3. ABDOMINAL OBESITY AND ECTOPIC FAT; 4. LIPOTOXICITY AND GLUCOTOXICITY; 5. MARKERS OF PROGRESSION FROM IGTTO TYPE 2 DIABETES; 6. CONCLUSIONS; REFEREN CES; Chapter 4: Primary Prevention Trials in Type 2 Diabetes; 1. INTRODUCTION; 1.1. Burden of Type 2 Diabetes; 2. PRIMARY PREVENTION OF DIABETES; 2.1. Risk Factors; 2.2. Types of Intervention; 3. INTERVENTION STRATEGIES
  • 3.1. Lifestyle Modification (LSM)3.2. The China Da Qing Study10; 3.3. The Finnish Diabetes Prevention Study (DPS)11; 3.4. The Diabetes Prevention Program (DPP)12/The DPP Outcome Study (DPPOS)20; 4. STUDIES IN ASIAN POPULATIONS; 4.1. The Indian Diabetes Prevention Programs (IDPP)13; 4.2. Japanese Diabetes Prevention Studies; 4.3. Malmo Feasibility Study22; 5. RECENT DEVELOPMENTS; 5.1. Efficacy of Mobile Phone Messaging in Prevention of Diabetes24; 6. STUDIES USING PHARMACOLOGICAL AGENTS; 6.1. Metformin; 6.2. Alpha Glucosidase Inhibitors; 6.3. Thiazolidinediones (TZD)
  • 6.4. The CAnadian Normoglycemia Outcomes Evaluation Trial316.5. Studies Using Other Drugs; 6.6. Antihypertensive Agents; 6.7. Safety of Pharmacological Agents; 7. MECHANISM OF ACTION OF INTERVENTION; 7.1. Cost-Effectiveness of Prevention Programs; 8. NATIONAL PROGRAMS; 9. CONCLUSIONS; REFERENCES; Chapter 5: Treatment of Prediabetes; 1. INTRODUCTION; 2. PATHOGENESIS OF T2DM; 2.1. Insulin Resistance; 2.2. Impaired β-Cell Function; 3. INSULIN RESISTANCE AND β-CELLFUNCTION IN IFG AND IGT; 4. INTERVENTION TO PREVENT THE PROGRESSION OF IGT TO T2DM; 4.1. Reversal of Insulin Resistance: Weight Loss
  • 4.2. Reversal of Insulin Resistance: Pharmacologic Intervention4.2.1. Metformin; 4.2.2. Thiazolidinediones (TZDs); 4.3. Preservation of β-Cell Function; 4.3.1. Glucagon-like Peptide-1 (GLP-1) Analogs; 4.3.2. DPP-IV inhibitors; 4.4. α-Glucosidase Inhibitors; 5. IDENTIFICATION OF HIGH-RISK IGT INDIVIDUALS FOR PHARMACOLOGICAL THERAPY; 6. APPROACH TO THE PATIENT WITH PREDIABETES; 7. SUMMARY; 8. CONCLUSION; REFERENCES; Chapter 6: Diabetes Prevention and Nutrition Policies from a Global Perspective; 1. INTRODUCTION; 2. PRIMARY PREVENTION; 2.1. Addressing Overweight and Obesity
  • 2.2. Increasing Physical Activity and Reducing Sedentary Behavior
Dimensions
unknown
Extent
1 online resource (498 p.)
Form of item
online
Isbn
9789814603324
Media category
computer
Media type code
  • c
Specific material designation
remote
System control number
  • (CKB)3710000000214664
  • (EBL)1766818
  • (SSID)ssj0001287768
  • (PQKBManifestationID)12486918
  • (PQKBTitleCode)TC0001287768
  • (PQKBWorkID)11291271
  • (PQKB)10125267
  • (MiAaPQ)EBC1766818
  • (WSP)00009170
  • (EXLCZ)993710000000214664

Library Locations

  • Albert D. Cohen Management LibraryBorrow it
    181 Freedman Crescent, Winnipeg, MB, R3T 5V4, CA
    49.807878 -97.129961
  • Architecture/Fine Arts LibraryBorrow it
    84 Curry Place, Winnipeg, MB, CA
    49.807716 -97.136226
  • Archives and Special CollectionsBorrow it
    25 Chancellors Circle (Elizabeth Dafoe Library), Room 330, Winnipeg, MB, R3T 2N2, CA
    49.809961 -97.131878
  • Bibliothèque Alfred-Monnin (Université de Saint-Boniface)Borrow it
    200, avenue de la Cathédrale, Local 2110, Winnipeg, MB, R2H 0H7, CA
    49.888861 -97.119735
  • Bill Larson Library (Grace Hospital)Borrow it
    300 Booth Drive, G-227, Winnipeg, MB, R3J 3M7, CA
    49.882400 -97.276436
  • Carolyn Sifton - Helene Fuld Library (St. Boniface General Hospital)Borrow it
    409 Tache Avenue, Winnipeg, MB, R2H 2A6, CA
    49.883388 -97.126050
  • Concordia Hospital LibraryBorrow it
    1095 Concordia Avenue, Winnipeg, MB, R2K 3S8, CA
    49.913252 -97.064683
  • Donald W. Craik Engineering LibraryBorrow it
    75B Chancellors Circle (Engineering Building E3), Room 361, Winnipeg, MB, R3T 2N2, CA
    49.809053 -97.133292
  • E.K. Williams Law LibraryBorrow it
    224 Dysart Road, Winnipeg, MB, R3T 5V4, CA
    49.811829 -97.131017
  • Eckhardt-Gramatté Music LibraryBorrow it
    136 Dafoe Road (Taché Arts Complex), Room 257, Winnipeg, MB, R3T 2N2, CA
    49.807964 -97.132222
  • Elizabeth Dafoe LibraryBorrow it
    25 Chancellors Circle, Winnipeg, MB, R3T 2N2, CA
    49.809961 -97.131878
  • Fr. H. Drake Library (St. Paul's College)Borrow it
    70 Dysart Road, Winnipeg, MB, R3T 2M6, CA
    49.810605 -97.138184
  • J.W. Crane Memorial Library (Deer Lodge Centre)Borrow it
    2109 Portage Avenue, Winnipeg, MB, R3J 0L3, CA
    49.878000 -97.235520
  • Libraries Annex (not open to the public; please see web page for details)Borrow it
    25 Chancellors Circle (in the Elizabeth Dafoe Library), Winnipeg, MB, R3T 2N2, CA
    49.809961 -97.131878
  • Neil John Maclean Health Sciences LibraryBorrow it
    727 McDermot Avenue (Brodie Centre), 200 Level, Winnipeg, MB, R3E 3P5, CA
    49.903563 -97.160554
  • Sciences and Technology LibraryBorrow it
    186 Dysart Road, Winnipeg, MB, R3T 2M8, CA
    49.811526 -97.133257
  • Seven Oaks General Hospital LibraryBorrow it
    2300 McPhillips Street, Winnipeg, MB, R2V 3M3, CA
    49.955177 -97.148865
  • Sister St. Odilon Library (Misericordia Health Centre)Borrow it
    99 Cornish Avenue, Winnipeg, MB, R3C 1A2, CA
    49.879592 -97.160425
  • St. John's College LibraryBorrow it
    92 Dysart Road, Winnipeg, MB, R3T 2M5, CA
    49.811242 -97.137156
  • Victoria General Hospital LibraryBorrow it
    2340 Pembina Highway, Winnipeg, MB, R3T 2E8, CA
    49.806755 -97.152739
  • William R Newman Library (Agriculture)Borrow it
    66 Dafoe Road, Winnipeg, MB, R3T 2R3, CA
    49.806936 -97.135525
Processing Feedback ...